<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04768478</url>
  </required_header>
  <id_info>
    <org_study_id>21-00069</org_study_id>
    <nct_id>NCT04768478</nct_id>
  </id_info>
  <brief_title>CBD for Pain Reduction and Opioid Use After Ankle and Tibia Fracture ORIF</brief_title>
  <official_title>The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Ankle and Tibia Fracture Open Reduction and Internal Fixation. A Double-Blind, Randomized Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of administering CBD to control&#xD;
      post-operative pain in patients undergoing ankle fracture open reduction and internal&#xD;
      fixation, tibial plafond (pilon) open reduction and internal fixation, tibial shaft repair&#xD;
      (open reduction internal fixation or intramedullary nail fixation), or tibial plateau open&#xD;
      reduction and internal fixation. Secondly, the purpose is to evaluate the effectiveness of&#xD;
      CBD in comparison with opioid therapy for post-operative pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score on Pain Visual Analog Scale (VAS)</measure>
    <time_frame>Day 2 Post-Surgery</time_frame>
    <description>Pain severity scores at rest will be assessed by use of a visual analog scale (VAS; total range = 0-10; 0 = no pain, 10 = worst pain imaginable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Score on Pain Visual Analog Scale (VAS)</measure>
    <time_frame>Day 7 Post-Surgery</time_frame>
    <description>Pain severity scores at rest will be assessed by use of a visual analog scale (VAS; total range = 0-10; 0 = no pain, 10 = worst pain imaginable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Score on Pain Visual Analog Scale (VAS)</measure>
    <time_frame>Day 14 Post-Surgery</time_frame>
    <description>Pain severity scores at rest will be assessed by use of a visual analog scale (VAS; total range = 0-10; 0 = no pain, 10 = worst pain imaginable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of Nausea Using VAS</measure>
    <time_frame>Day 2 Post-Surgery</time_frame>
    <description>Any nausea experienced by the patients will be recorded by use of a VAS (total range = 0-10; 0 = no nausea, 10 = worst nausea imaginable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of Nausea Using VAS</measure>
    <time_frame>Day 7 Post-Surgery</time_frame>
    <description>Any nausea experienced by the patients will be recorded by use of a VAS (total range = 0-10; 0 = no nausea, 10 = worst nausea imaginable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of Nausea Using VAS</measure>
    <time_frame>Day 14 Post-Surgery</time_frame>
    <description>Any nausea experienced by the patients will be recorded by use of a VAS (total range = 0-10; 0 = no nausea, 10 = worst nausea imaginable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CBD Consumption</measure>
    <time_frame>Day 2 Post-Surgery</time_frame>
    <description>Patient self report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CBD Consumption</measure>
    <time_frame>Day 7 Post-Surgery</time_frame>
    <description>Patient self report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CBD Consumption</measure>
    <time_frame>Day 14 Post-Surgery</time_frame>
    <description>Patient self report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>Day 2 Post-Surgery</time_frame>
    <description>Patient self report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>Day 7 Post-Surgery</time_frame>
    <description>Patient self report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>Day 14 Post-Surgery</time_frame>
    <description>Patient self report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction Score</measure>
    <time_frame>Day 14 Post-Surgery</time_frame>
    <description>Patients will record their satisfaction with their management, on a 0-10 scale. The higher the score, the higher the satisfaction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Ankle Fractures</condition>
  <condition>Tibia Fracture</condition>
  <arm_group>
    <arm_group_label>Cannabidiol (CBD)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBD</intervention_name>
    <description>25mg CBD ODTs (orally disintegrating tablet), with instructions to take CBD tablets t.i.d. (total of 50mg per dose t.i.d.) to be administered with routine post-operative pain management</description>
    <arm_group_label>Cannabidiol (CBD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Visually indistinguishable placebo ODTs, with instructions to take two tablets t.i.d., to be administered with routine post-operative pain management</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing an ankle fracture open reduction and internal fixation (medial&#xD;
             malleolus, lateral malleolus, posterior malleolus, and/or syndesmosis repair), tibial&#xD;
             plafond (pilon) open reduction and internal fixation, tibial shaft repair (open&#xD;
             reduction internal fixation and intramedullary nail fixation), or tibial plateau open&#xD;
             reduction and internal fixation&#xD;
&#xD;
          -  Patients ages 18-75, inclusive&#xD;
&#xD;
          -  Female patients must be currently practicing effective forms of two types of birth&#xD;
             control, which are defined as those, alone or in combination, that result in a low&#xD;
             failure rate (less than 1% per year) when used consistently and correctly&#xD;
&#xD;
          -  Male patients must be using an effective form of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Legally incompetent or mentally impaired (e.g., minors, Alzheimer's subjects,&#xD;
             dementia, etc.)&#xD;
&#xD;
          -  Younger than 18 years of age&#xD;
&#xD;
          -  Older than 75 years of age&#xD;
&#xD;
          -  Any patient considered a vulnerable subject: pregnant women or fetuses, children,&#xD;
             cognitively impaired adults, prisoners&#xD;
&#xD;
          -  History of cannabis abuse or dependence&#xD;
&#xD;
          -  History of coagulation abnormalities and thromboembolic disease or current abnormal&#xD;
             coagulation test values&#xD;
&#xD;
          -  History of stroke or acute coronary syndromes within 3 months before surgery&#xD;
&#xD;
          -  Abnormal coagulation profile&#xD;
&#xD;
          -  Renal failure (serum creatinine &gt; 250 Î¼mol/L [2.83 mg/dL]) or liver cirrhosis&#xD;
&#xD;
          -  Patients that have been on pre-operative opioid management for any reason&#xD;
&#xD;
          -  Patients meeting the DSM-V for major psychiatric illness, such as bipolar disorder&#xD;
&#xD;
          -  Patients diagnosed with major depression, psychosis, or substance abuse disorder&#xD;
&#xD;
          -  Patients with current or a history of suicidal ideation&#xD;
&#xD;
          -  Breastfeeding females&#xD;
&#xD;
          -  Patients with clinically significant illness, including cardiovascular disorders&#xD;
&#xD;
          -  Clinically significant lab abnormalities&#xD;
&#xD;
          -  Abnormal LFTs&#xD;
&#xD;
          -  Patients with major neurological disorders, such as dementia, Parkinson's disease,&#xD;
             cognitive impairment, epilepsy, history of traumatic brain/head injury, or seizures&#xD;
&#xD;
          -  Patients with moderate (Child-Pugh B) and severe hepatic impairment (Child-Pugh C).&#xD;
&#xD;
          -  Patients taking moderate or strong inhibitors of CYP3A4 and CYP2C19 concomitantly&#xD;
&#xD;
          -  Patients taking strong CYP3A4 and CYP2C19 inducers concomitantly&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Leucht, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ariel Aponte</last_name>
    <phone>212-460-0176</phone>
    <email>Ariel.Apointe@nyulangone.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>NYU Langone Orthopedic Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ariel Aponte</last_name>
      <phone>212-460-0176</phone>
      <email>Ariel.Apointe@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Philipp Leucht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Alaia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cannabidiol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Ankle Fractures</mesh_term>
    <mesh_term>Tibial Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared upon reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to Philipp.Leucht@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

